

**Docket #:** S22-104

# **Synthetic Transcription Elongation Factors to Target Mutations in Cancer Genomes**

Researchers at Stanford have developed synthetic transcription elongation factors (Syn-TEFs) to treat proliferative diseases, including repeat expansion mutations in cancer. Repeat expansions are believed to contribute to cancer proliferation but many are considered untreatable by available therapeutics. Syn-TEFs have previously been shown to treat devastating neurodegenerative diseases. The newly reported Syn-TEFs are bifunctional compounds that specifically target GAAA repeats linked to cancer. They consist of a pyrrole/imidazole polyamide and a bromodomain inhibitor, and have demonstrated anti-proliferative effects in kidney cancer in vitro. This work supports the development of personalized therapies that target cancer DNA mutations directly. Since Syn-TEFs are modular in nature, the DNA-binding polyamide can easily be modified to target any DNA sequence of interest, including any repeat expansions identified in cancer.

## **Stage of Development**

The researchers have demonstrated anti-proliferative activity in cancer cell lines.

## **Applications**

- Small molecule development in oncology

## **Advantages**

- Many repeat expansions considered untreatable by available therapeutics.
- Syn-TEFs are targeted and modular, allowing the DNA-binding polyamide to be modified.

- Can be used as a template for personalized anti-cancer therapy.

## **Patents**

- Published Application: [20230322853](#)

## **Innovators**

- Graham Erwin
- Michael Snyder

## **Licensing Contact**

### **Tariq Arif**

Senior Associate Director, Life Sciences

[Email](#)